In Vivo's Deals Of The Month, February 2017

Seattle Genetics Inc., the first company to gain FDA approval for an antibody-drug conjugate, has licensed rights to a breast cancer ADC that has been designated a potential breakthrough therapy. Seattle will pay $250 million up front to Immunomedics Inc. for global rights to sacituzumab govitecan (IMMU-132). Immunomedics can earn development, regulatory and sales-based milestone payments up to $1.7 billion, along with tiered double-digit royalties. Seattle also purchased a 2.8% equity stake in Immunomedics and can buy 8.7 million additional shares in the company through an unspecified date. [See Deal]

Sarepta Therapeutics Inc. has sold the voucher it received upon approval of its Duchenne muscular dystrophy treatment Exondys 51...